Chen Gong,Zhu Ye,Wu Shaojing.Applications and future prospects of drugs related to bile acid metabolism in biliary atresia[J].Journal of Clinical Pediatric Surgery,2020,19(06):473-476.[doi:10.3969/j.issn.1671-6353.2020.06.002]
胆汁酸代谢相关药物在胆道闭锁治疗中的应用与展望
- Title:
- Applications and future prospects of drugs related to bile acid metabolism in biliary atresia
- 关键词:
- 胆道闭锁; 胆汁酸类和盐类/治疗应用
- Keywords:
- Biliary Atresia; Bile Acids and Salts/TU
- 分类号:
- R722;R575.7;R725.7
- 摘要:
- 胆道闭锁患儿胆汁酸代谢异常可损伤肝细胞及胆管上皮细胞。熊去氧胆酸作为目前胆道闭锁手术后常规用药，其疗效及使用方法仍存在争议；胆汁酸甾体类核受体激动剂（奥贝胆酸）及非甾体类核受体激动剂（LJN-452）、肠道胆汁酸重吸收相关蛋白调控药物（A4250）、肝脏内胆汁酸转运蛋白、肾脏转运蛋白相关药物的开发研究近年来发展迅速，不少药物已开始临床Ⅱ、Ⅲ期试验，将来可能对胆道闭锁肝门空肠吻合术后逐步恢复胆流的患儿有一定帮助，成为胆道闭锁肝门空肠吻合术后新辅助用药。
- Abstract:
- Abnormal bile acid metabolism in biliary atresia (BA) may injure hepatocytes and bile duct epithelial cells.Ursodeoxycholic acid is currently a standard postoperative drug for BA.However,its efficacy and dosing have remained controversial.Steroidal bile acid nuclear receptor activation (obeticholic acid,etc),non-steroidal nuclear receptor agonist (LJN-452,etc),intestinal bile acid reabsorption related protein regulating drug (A4250,etc),liver bile acid transporter and kidney transporter related drugs have been developed rapidly in recent years.Many candidates have entered phase Ⅱ/Ⅲ clinical trials.In the future,these promising drugs may benefit children gradually recovering bile flow after Kasai procedure.They may become new adjuvant drugs for BA.
参考文献/References:
1 Javitt NB,Keating JP,Grand RJ,et al.Serum bile acid patterns in neonatal hepatitis and extrahepatic biliary atresia[J].J Pediatr,1977,90(5):736-739.DOI:10.1016/s0022-3476(77)81238-9.
2 Golden J,Zagory JA,Fenlon M,et al.Liquid chromatography-mass spectroscopy in the diagnosis of biliary atresia in children with hyperbilirubinemia[J].J Surg Res,2018,228:228-237.DOI:10.1016/j.jss.2018.03.021.
3 Obatake M,Muraji T,Satoh S,et al.Urinary sulfated bile acids:A new simple urine test for cholestasis in infants and children[J].J Pediatr Surg,2002,37(12):1707-1708.DOI:10.1053/jpsu.2002.36701.
4 Zhou K,Wang J,Xie G,et al.Distinct plasma bile acid profiles of biliary atresia and neonatal hepatitis syndrome[J].J Proteome Res,2015,14(11):4844-4850.DOI:10.1021/acs.jproteome.5b00676.
5 Wang ZM,Chen YJ,Peng CH,et al.Five-year native liver survival analysis in biliary atresia from a single large chinese center:the death/liver transplantation hazard change and the importance of rapid early clearance of jaundice[J].J Pediatr Surg,2019,54(8):1680-1685.DOI:10.1016/j.jpedsurg.2018.09.025.
6 姜璟[XCBZ.TIF],郑珊.熊去氧胆酸在胆道闭锁辅助治疗中的研究进展[J].临床小儿外科杂志,2018,17(12):954-958.DOI:10.3969/j.issn.1671-6353.2018.12.017.Jiang JY,Zheng S.Research advances of using ursodeoxycholic acid in the supplemental treatment of biliary atresia[J].J Clin Ped Sur,2018,17(12):954-958.DOI:10.3969/j.issn.1671-6353.2018.12.017.
7 Nittono H,Tokita A,Hayashi M,et al.Ursodeoxycholic acid therapy in the treatment of biliary atresia[J].Biomed Pharmacother,1989,43(1):37-41.DOI:10.1016/0753-3322(89)90189-3.
8 Qiu JL,Shao MY,Xie WF,et al.Effect of combined ursodeoxycholic acid and glucocorticoid on the outcome of kasai procedure:A systematic review and meta-analysis[J].Medicine (Baltimore),2018,97(35):e12005.DOI:10.1097/md.0000000000012005.
9 Hasegawa Y,Kawai M,Bessho K,et al.CYP7A1 expression in hepatocytes is retained with upregulated fibroblast growth factor 19 in pediatric biliary atresia[J].Hepatol Res,2019,49(3):314-323.DOI:10.1111/hepr.13245.
10 Van Golen RF,Olthof PB,Lionarons DA,et al.FXR agonist obeticholic acid induces liver growth but exacerbates biliary injury in rats with obstructive cholestasis[J].Sci Rep,2018,8(1):16529.DOI:10.1038/s41598-018-33070-1.
11 Han CY.Update on FXR biology:Promising therapeutic target?[J].Int J Mol Sci,2018,19(7):2069.DOI:10.3390/ijms19072069.
12 Fiorucci S,Di GiorgioC,Distrutti E.Obeticholic acid:An update of its pharmacological activities in liver disorders[J].Handb Exp Pharmacol,2019,256:283-295.DOI:10.1007/164_2019_227.
13 Lv B,Ma L,Tang W,et al.FXR acts as a metastasis suppressor in intrahepatic cholangiocarcinoma by inhibiting il-6-induced epithelial-mesenchymal transition[J].Cell Physiol Biochem,2018,48(1):158-172.DOI:10.1159/000491715.
14 Fan YY,Ding W,Zhang C,et al.Obeticholic acid prevents carbon tetrachloride-induced liver fibrosis through interaction between farnesoid X receptorand Smad3[J].Int Immunopharmacol,2019,77:105911.DOI:10.1016/j.intimp.2019.105911.
15 Cipriani S,Mencarelli A,Palladino G,et al.FXR activation reverses insulin resistance and lipid abnormalities and protects against liver steatosis in Zucker (fa/fa) obese rats[J].J Lipid Res,2010,51(4):771-784.DOI:10.1194/jlr.M001602.
16 Wang YD,Chen WD,Wang M,et al.Farnesoid X receptor antagonizes nuclear factor kappab in hepatic inflammatory response[J].Hepatology,2008,48(5):1632-1643.DOI:10.1002/hep.22519.
17 Tully DC,Rucker PV,Chianelli D,et al.Discovery of tropifexor (LJN452),a highly potent non-bile acid FXR agonist for the treatment of cholestatic liver diseases and nonalcoholic steatohepatitis (NASH)[J].J Med Chem,2017,60(24):9960-9973.DOI:10.1021/acs.jmedchem.7b00907.
18 Graffner H,Gillberg PG,Rikner L,et al.The ileal bile acid transporter inhibitor A4250 decreases serum bile acids by interrupting the enterohepatic circulation[J].Aliment Pharmacol Ther,2016,43(2):303-310.DOI:10.1111/apt.13457.
19 Baumann U,Sturm E,Lacaille F,et al.Effects of the ileal bile acid transport inhibitor A4250 on pruritus and serum bile acids in patients with biliary atresia:phase 2 study results[C].EASL,2019.
20 Hegade VS,Kendrick SF,Dobbins RL,et al.BAT117213:Ileal bile acid transporter (IBAT) inhibition as a treatment for pruritus in primary biliary cirrhosis:Study protocol for a randomised controlled trial[J].BMC Gastroenterol,2016,16(1):71.DOI:10.1186/s12876-016-0481-9.
21 Slijepcevic D,Roscam Abbing RLP,Fuchs CD,et al.Na(+)-taurocholate cotransporting polypeptide inhibition has hepatoprotective effects in cholestasis in mice[J].Hepatology,2018,68(3):1057-1069.DOI:10.1002/hep.29888.
相似文献/References:
[1]毛永忠,汤绍涛,阮庆兰,等.胆道闭锁肝组织MMP-1、MMP-2、TIMP-1的表达与预后研究[J].临床小儿外科杂志,2007,6(01):5.
[2]毛永忠,汤绍涛,阮庆兰,等.胆道闭锁肝脏组织MMP-2、TGF-β_1的表达及意义[J].临床小儿外科杂志,2007,6(03):5.
[3]余梦楠 刘钢 黄柳明 王伟. 胆道闭锁术后反复发作性胆管炎的细菌谱分析及抗生素选择[J].临床小儿外科杂志,2012,11(03):187.
[J].Journal of Clinical Pediatric Surgery,2012,11(06):187.
[4]董淳强 杨体泉 董昆. 胆道闭锁术后早期胆管炎风险因素分析[J].临床小儿外科杂志,2013,12(05):348.
[5]陈功 郑珊 孙松. 不同年龄胆道闭锁患儿手术效果分析[J].临床小儿外科杂志,2014,13(01):22.
[6]谭梅军 陶强 黄金狮. IL-17在胆道闭锁患儿肝组织中的表达及意义[J].临床小儿外科杂志,2014,13(04):302.
[7]杨文萍 吴艳 张守华. 胆道闭锁患者肝脏组织病理改变的综合评价[J].临床小儿外科杂志,2015,14(01):10.
[8]李康 阳历 汤绍涛. 胆道闭锁患者肝内胆管γδT 细胞和调节性T细胞浸润及意义[J].临床小儿外科杂志,2015,14(01):16.
[9]刘丹丹 詹江华 高伟. 胆道闭锁患者肝门的病理解剖学研究[J].临床小儿外科杂志,2015,14(01):20.
[10]张震 李龙 乔国梁. 胆道闭锁Kasai术后生存率及条件生存率分析[J].临床小儿外科杂志,2015,14(01):25.
备注/Memo
收稿日期:2020-03-20。
基金项目:国家自然科学基金（编号：81873545）；国家自然科学基金（编号：81974059）；上海市科委引导项目（编号：18411969100）；医苑新星（编号：EK00000622）
作者简介:陈功,Email:chengongzlp@hotmail.com